Editorial: Save the Stem Cells
By The Daily Californian,
The Daily Californian
| 10. 04. 2005
UC likes living on the technological edge. So when California allocated funds for stem cell research as mandated by Proposition 71, UC was one of the first that stood to benefit. With our help, such research could lead to breakthrough drugs for cancer and congenital diseases. But in its haste to see some returns on this endeavor, the state legislature may make a big mistake by adopting provisions of the 1980 Bayh-Dole Patent and Trademark Act.
This federal law was designed to give universities more leeway in taking lab work to market. The act allowed universities to patent federally funded research and license the results to companies, helping to develop their findings for profit.
Bayh-Dohl didn't exactly break new ground: Universities have always had close relationships with related industries. Professors at some universities even get a day off per week to consult with them.
But Bayh-Dole benefits industry more than it helps universities. The act has changed the way universities conduct research, giving rise to complex corporate relationships. Even now, the stem-cell board that doles out funds cannot give UC...
Related Articles
By Matt Novak, Gizmodo | 07.23.2025
Robert F. Kennedy Jr., the Secretary of Health and Human Services, has made a big push to get agencies like the Food and Drug Administration to use generative artificial intelligence tools. In fact, Kennedy recently told Tucker Carlson that AI...
By Keith Casebonne and Jodi Beckstine [with CGS' Katie Hasson], Disability Deep Dive | 07.24.2025
In this episode of Disability Deep Dive, hosts Keith and Jodi explore the complex interplay between disability science, technology, and ethics with guest Katie Hasson, Associate Director at the Center for Genetics and Society. The conversation delves into...
By Angus Liu, Fierce Pharma | 07.22.2025
A brief skirmish between Sarepta Therapeutics and the FDA has ended before escalating into a full-on regulatory clash, as the company has bowed to the agency’s demand.
In a surprising reversal, Sarepta on Monday said it will pause all shipments...
By Lucy Tu, The Atlantic | 07.11.2025
Donald Trump—who is, by his own accounting, “the fertilization president” and “the father of IVF”—wants to help Americans reproduce. During his 2024 campaign, he promised that the government or insurance companies would cover the cost of in vitro fertilization. In...